Aptahem finalizes Part 1a of the FIH study for its lead candidate Apta-1
Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases such as sepsis, announces today the finalization of FIH (First In Human) Part 1a study.This decision is based on the data of the extra analyses leading to a more complete understanding of Apta-1´s mechanism of action. The decision will potentially save time moving forward with the clinical development program. The Phase 1a study is a so called dubble blind study and analysis and compilation of the unblinded results will now commence. Aptahem will present preliminary data when